Efficacy and Safety of Rivaroxaban versus Warfarin for the Treatment of Acute Pulmonary Embolism: A Real-World Study

Table 3

Efficacy in patients receiving the expected course of treatment.

Duration	Efficacy		Rivaroxaban (52)	Warfarin (23)		value
1 month	Disappeared	27	22 (42.31%)	5 (21.74%)	1.8740	0.1710
	Effective	30	20 (38.46%)	10 (43.48%)	0.1003	0.7514
	No effect or progressed	6	4 (7.69%)	2 (8.7%)	0.0201	0.8874
	—	12	6 (11.54%)	6 (26.09%)
3 months	Disappeared	38	30 (57.69%)	8 (34.78%)	1.6519	0.1987
	Effective	19	13 (25%)	6 (26.09%)	0.0074	0.9313
	No effect or progressed	9	6 (11.54%)	3 (13.04%)	0.0301	0.8623
	—	9	3 (5.77%)	6 (26.09%)
6 months	Disappeared	39	31 (59.62%)	8 (34.78%)	1.8911	0.1691
	Effective	19	11 (21.15%)	8 (34.78%)	1.1692	0.2796
	No effect or progressed	7	5 (9.62%)	2 (8.7%)	0.0145	0.9043
	—	10	5 (9.62%)	5 (21.74%)